ZabBio, Inc.

ZabBio, Inc. is a health care and pharmaceutical startup established in 2017 and headquartered in the United States. The company is dedicated to developing monoclonal antibody-based products to address unmet needs in infectious diseases and reproductive health. With a focus on production at scale and cost, ZabBio aims to cater to large, cost-sensitive markets. The core team boasts extensive experience, having conducted previous clinical trials such as those of MB66 (IND # 122,010) and ZB06 (IND # 147,498), covering drug manufacture, designing nonclinical studies, regulatory filings, and overseeing Phase 1 trials. The collective experience of the team spans over 20 years in antibody discovery, engineering, manufacture, and nonclinical and clinical trials. Although the last investment and investors are currently undisclosed, ZabBio's innovative approach to addressing critical health concerns in a cost-effective manner presents potential for growth and impact in the pharmaceutical industry.